Skip Ribbon Commands
Skip to main content


MASTER DAPT has met the three coprimary endpoints:

Discontinuation of DAPT 1 month after the implantation of an Ultimaster™ family DES was non-inferior to the continuation of DAPT for ≥2 additional months with regard to net adverse clinical events and major adverse cardiac or cerebral events. Furthermore, abbreviated DAPT was superior to standard-therapy DAPT with regards to major or clinically relevant nonmajor bleeding.

See the full results on Total Population

  • ​1-month DAPT had a similar effect on NACE and MACCE in patients with or without OAC therapy
  • Bleeding risk was significantly reduced after 1-month DAPT in HBR patients without OAC. Only a numerically lower bleeding risk, (but not statistically significant) was observed in the OAC population.
  • MASTER  DAPT results show that is safe and beneficial to stop DAPT at 1 month after Ultimaster™ Family DES in HBR patients with or without an indication for OAC

Discover the full results for the other subgroups recently published.

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Upcoming events

Mauris sed purus volutpat, convallis nibh ac, feugiat lorem. Sed dignissim arcu eulala.

CIRSE 2023
September 9 - 13 Copenhagen, Denmark
All events

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.